Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.

Slides:

Advertisements

Similar presentations

JOURNAL REVIEW Newer Antithrombotics in AF 1 Dr Ranjith MP Senior Resident Department of Cardiology Government Medical college Kozhikode.

Advertisements

Georges Ghanem MD, FESC, FACC Associate Professor, Chief of Cardiology UMC-RH/LAU-SOM Beirut, Lebanon.

Prof. Alberto Corsini Università degli Studi di Milano

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,

Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective by Michael D. Ezekowitz, Rangadham.

Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated with Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.

Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Non-valvular Atrial Fibrillation.

Heart, Lung and Circulation

American Heart Journal

Volume 28, Issue 6, Pages (December 2012)

RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.

Hydroxyurea makes inflammation “just right”?

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of.

TCR-MHC-peptide(s): in vivo veritas

CD25 expression is associated with unfavorable clinical outcome.

A Systematic Review On Different Prothrombin Complex Concentrate Strategies To Reverse Vitamin K Antagonist Therapy by Nakisa Khorsand, Hilde A.M. Kooistra,

BRAF inhibitor: targeted therapy in hairy cell leukemia

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

Pregnancy outcomes after maternal exposure to rituximab

by Corey S. Cutler, John Koreth, and Jerome Ritz

A Study or Subgroup Apixaban Larsen et al.52 Nielsen et al.53

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

by Fangxin Hong, Thomas M Habermann, Leo I

Dabigatran vs Warfarin in Patients with Atrial Fibrillation – Results

Daniel Frenkel et al. JACEP 2016;2:

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Hepatitis C infection among survivors of childhood cancer

How I treat refractory CLL

Activity of eltrombopag in severe aplastic anemia

by Hideki Yoshioka, Hiromi Sato, Hiroto Hatakeyama, and Akihiro Hisaka

Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma by Young Ae Kim, Ja Min Byun, Keeho Park, Gi Hwan Bae, Dukhyoung.

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes by Chi-Yuan Yao, Ching-Hsuan Chen, Huai-Hsuan Huang, Hsin-An Hou, Chien-Chin.

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories by Sanam Loghavi, Dawen Sui, Peng Wei, Guillermo Garcia-Manero, Sherry.

Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group by Tao Wu, Yong Yang, Su-Yu.

by Kaiwen Chen, Matthew P. Cheng, Sarah P

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide by Shannon R. McCurdy, Mei-Jie Zhang, Andrew.

Volume 2(Supplement 1):1-3

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia by Saurabh Chhabra, Kwang Woo.

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma by Sham Mailankody, Dickran Kazandjian, Neha Korde,

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM by Sundar Jagannath, Rafat Abonour,

by Christine L. Kempton, and Amanda B. Payne

by Terra L. Lasho, Mythri Mudireddy, Christy M. Finke, Curtis A

Volume 2(Supplement 1):46-49

Malglycemia is associated with poor outcomes in pediatric and adolescent hematopoietic stem cell transplant patients by Jenna Sopfe, Laura Pyle, Amy K.

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma by Nidhi Tandon, Surbhi Sidana, S. Vincent Rajkumar,

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry by Donald M. Arnold, Ishac Nazy, Rumi.

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

Pamela E. Scott et al. JACC 2018;71:

Volume 2(Supplement 1):39-41

Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis by Rasha Khatib, Maja Ludwikowska, Daniel.

PD-L1 and tumor-associated macrophages in de novo DLBCL

Pamela E. Scott et al. JACC 2018;71:

by Matthew S. Painschab, Kate D

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.

Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease by Joshua J. Field, Elaine Majerus, Victor.

CR-rate ratios with 95% CIs

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.

Gianluigi Savarese et al. JCHF 2016;4:

Forest plot illustrating the risk ratio of major bleeding

by Renato D. Lopes, Patrícia O. Guimarães, Bradley J. Kolls, Daniel M

New concepts for anticoagulant therapy in persons with hemophilia

Presentation transcript:

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne H. Datta, Pamela L. Lutsey, Richard F. MacLehose, Lin Y. Chen, and Alvaro Alonso BloodAdv Volume 2(3):200-209 February 13, 2018 © 2018 by The American Society of Hematology

Professional illustration by Patrick Lane, ScEYEnce Studios. Surbhi Shah et al. Blood Adv 2018;2:200-209 © 2018 by The American Society of Hematology

Adjusted HRs (95% CIs) of outcomes among anticoagulant users, stratified by subgroups: rivaroxaban vs warfarin users. Adjusted HRs (95% CIs) of outcomes among anticoagulant users, stratified by subgroups: rivaroxaban vs warfarin users. Surbhi Shah et al. Blood Adv 2018;2:200-209 © 2018 by The American Society of Hematology

Adjusted HRs (95% CIs) of outcomes among anticoagulant users, stratified by subgroups: dabigatran vs warfarin users. Adjusted HRs (95% CIs) of outcomes among anticoagulant users, stratified by subgroups: dabigatran vs warfarin users. Surbhi Shah et al. Blood Adv 2018;2:200-209 © 2018 by The American Society of Hematology

Adjusted HRs (95% CIs) of outcomes among anticoagulant users, stratified by subgroups: apixaban vs warfarin users. Adjusted HRs (95% CIs) of outcomes among anticoagulant users, stratified by subgroups: apixaban vs warfarin users. Surbhi Shah et al. Blood Adv 2018;2:200-209 © 2018 by The American Society of Hematology